Mereo BioPharma (MREO) Gross Margin (2023 - 2025)

Mereo BioPharma (MREO) posted quarterly Gross Margin of 80.0% for Q2 2025, down 37.16% quarter-over-quarter from 127.3% in Q4 2023.

Mereo BioPharma (MREO) Gross Margin (2023 - 2025) Analysis & Trends

Mereo BioPharma (MREO) has reported Gross Margin for 2 consecutive years, with 80.0% the latest figure, recorded in Q2 2025.

In Q2 2025, Gross Margin changed N/A year-over-year to 80.0%; the TTM figure through Dec 2025 stood at 80.0% (changed N/A YoY), while the FY2025 annual figure was 73.4%, changed N/A from the prior year.
Gross Margin fell to 80.0% in Q2 2025 per MREO's latest filing, from 127.3% in the prior quarter.
Across five years, Gross Margin topped out at 127.3% in Q4 2023 and bottomed at 61.89% in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	138.57 Bn	130.72 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	85.98 Bn	77.99 Bn	3.93 Bn	91.59%
3	Argenx Se	65.11 Bn	59.92 Bn	1.37 Bn	90.43%
4	Moderna	55.73 Bn	50.59 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.64 Bn	28.33 Bn	992.69 Mn	76.90%
7	BioNTech SE	27.70 Bn	9.31 Bn	668.28 Mn	63.27%
8	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.32 Bn	26.49 Bn	-	-
10	Mereo BioPharma	47.30 Mn	47.30 Mn	-	-

Download Data